| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 2,523 | 1,778 | 1,529 | 1,810 |
| Cost of revenues | 1,659 | 1,465 | 1,237 | 1,396 |
| Gross profit | 864 | 313 | 292 | 414 |
| Research and development | 3,635 | 3,834 | 4,059 | 3,915 |
| Selling and marketing | 4,392 | 4,172 | 2,750 | 1,472 |
| General and administrative | 5,888 | 5,326 | 4,943 | 3,489 |
| Total operating expenses | 13,915 | 13,332 | 11,752 | 8,876 |
| Loss from operations | -13,051 | -13,019 | -11,460 | -8,462 |
| Financial income, net | 343 | -132 | 294 | 572 |
| Net loss | -12,708 | -13,151 | -11,166 | -7,890 |
| Net loss per share - basic | -0.17 | -0.26 | -0.22 | -0.16 |
| Net loss per share - diluted | -0.17 | -0.26 | -0.22 | -0.16 |
| Weighted average number of ordinary shares used in computing net loss per share - basic | 73,466,501 | 51,003,900 | 49,993,509 | 48,369,412 |
| Weighted average number of ordinary shares used in computing net loss per share - diluted | 73,466,501 | 51,003,900 | 49,993,509 | 48,369,412 |
InspireMD, Inc. (NSPR)
InspireMD, Inc. (NSPR)